Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18972246 | TRADITIONAL CHINESE HERBAL COMPOSITION FOR TREATMENT OF BACTERIAL VAGINOSIS AND PREPARATION METHOD THEREOF | December 2024 | February 2025 | Allow | 2 | 0 | 0 | No | No |
| 18467250 | TRADITIONAL CHINESE MEDICINE OINTMENT FOR PREVENTING AND TREATING MASTITIS IN DAIRY COWS, AND PREPARATION METHOD THEREOF | September 2023 | November 2024 | Allow | 14 | 2 | 1 | No | No |
| 18141249 | Production of Ethanol-free Vanilla Extracts | April 2023 | February 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18307570 | BEETROOT-CONTAINING COMPOSITION | April 2023 | March 2024 | Allow | 11 | 0 | 1 | Yes | No |
| 18129647 | METHOD AND COMPOSITION FOR PRODUCTION OF A PHYTONUTRIENT IN A MICROBIOME | March 2023 | January 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18126519 | COMPOSITIONS COMPRISING FUCOXANTHIN AND USE THEREOF IN REDUCTION OF FAT ACCUMULATION IN CELLS | March 2023 | May 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18156431 | HERBAL COMPOSITION FOR TREATMENT OF ACIDITY AND INDIGESTION PROBLEM | January 2023 | July 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18089896 | COMPOSITIONS COMPRISING THEANINE, MAGNOLIA, AND PHELLODENDRON | December 2022 | June 2024 | Allow | 18 | 0 | 2 | Yes | No |
| 18073535 | REPELLANT FORMULATION AND METHOD | December 2022 | March 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 18073538 | REPELLANT FORMULATION AND METHOD | December 2022 | March 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 17966912 | PROCESS FOR PRESERVING THE HUSK AND USE OF RAMBUTAN (NEPHELIUM LAPPACEUM) IN FOOD PRODUCTS | October 2022 | April 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17966924 | PROCESS FOR PRESERVING THE HUSK AND USE OF RAMBUTAN (NEPHELIUM LAPPACEUM) IN FOOD PRODUCTS | October 2022 | July 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17963888 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GYNECOLOGICAL DISEASES CONTAINING SARCODON ASPRATUS EXTRACTS AS ACTIVE INGREDIENT | October 2022 | September 2023 | Allow | 11 | 0 | 0 | No | No |
| 17960503 | USE OF POLYPHENOL CONTAINING SUGAR CANE EXTRACTS FOR PREVENTING, IMPROVING OR TREATING A SKIN CONDITION | October 2022 | March 2025 | Allow | 30 | 3 | 1 | No | No |
| 17947012 | TOPICAL COMPOSITIONS FOR ENHANCING A MAN'S SEXUAL RESPONSIVENESS AND PERFORMANCE | September 2022 | June 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17898017 | METHODS FOR ENHANCING SLEEP QUALITY | August 2022 | August 2024 | Abandon | 23 | 3 | 0 | No | No |
| 17819705 | BOTANICAL ANTIVIRAL NUTRITIONAL SUPPLEMENT | August 2022 | July 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17885579 | TRADITIONAL CHINESE MEDICINE EYE DROPS AND THE PREPARATION METHOD THEREOF | August 2022 | April 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 17759122 | PLANT-BASED COMPOSITION IN A FORM SUITABLE FOR TOPICAL ADMINISTRATION AND ASSOCIATED PRODUCTION METHOD | July 2022 | May 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17868704 | COMPOSITION FOR ENHANCING IMMUNITY OR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES BY USING GOJI BERRIES, MULBERRIES AND JUJUBES | July 2022 | July 2023 | Allow | 12 | 1 | 1 | Yes | No |
| 17859028 | TRADITIONAL CHINESE MEDICINE COMPOUND COMPOSITION WITH EFFECT OF IMPROVING MALE SEXUAL FUNCTION AND APPLICATION THEREOF | July 2022 | July 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17860079 | TIBETAN FOUR-INGREDIENT LUNG-CLEARING MIXTURE AND APPLICATION THEREOF IN PREPARING MEDICATION FOR TREATING RESPIRATORY DISEASES | July 2022 | January 2025 | Abandon | 31 | 2 | 0 | No | No |
| 17856956 | Hepatoprotective Effects of Palauan Folk Medicine | July 2022 | July 2024 | Abandon | 24 | 2 | 0 | Yes | No |
| 17779680 | COMPOSITION FOR PREVENTING OR TREATING HYPERTENSION | May 2022 | April 2025 | Allow | 35 | 1 | 1 | No | No |
| 17725587 | Honey Foam | April 2022 | March 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17770048 | PROCESS FOR THE PRODUCTION OF TAMARIND EXTRACT | April 2022 | June 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17721908 | COMPOSITION OF MATTER AND METHODS FOR A FECAL-DERIVED STERILIZED PREBIOTIC AND POSTBIOTIC | April 2022 | March 2025 | Allow | 38 | 5 | 1 | Yes | No |
| 17767604 | Composition For Preventing Or Treating Neurodegenerative Diseases Containing Mixed Herbal Extract Of Genkwae Flos, Clematidis Radix, And Gastrodiae Rhizoma | April 2022 | May 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17706270 | HEALTH BENEFITING COMPOSITIONS OF DAILY NUTRITION AND METHODS OF USE THEREOF | March 2022 | February 2024 | Allow | 23 | 2 | 1 | No | No |
| 17640677 | THERAPEUTIC AGENT FOR MYOCARDITIS | March 2022 | June 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17637915 | COMPOSITION FOR AMELIORATING PREMENSTRUAL SYNDROME SYMPTOMS, INCLUDING CHRYSANTHEMUM ZAWADSKII EXTRACT | February 2022 | October 2024 | Allow | 32 | 3 | 0 | Yes | No |
| 17588211 | SYSTEMS AND METHODS FOR PRODUCING A KAVA LIQUID DIETARY SUPPLEMENT | January 2022 | April 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17587535 | TREATMENT OF AGING OR UV-DAMAGED SKIN | January 2022 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17631320 | PREPARATION COMPRISING OMEGA-3 FATTY ACID SALTS AND EXTRACTS OF GUM RESINS FROM BOSWELLIA SPECIES | January 2022 | January 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17585612 | METHOD FOR IMPROVING BODY SHAPE AND IMPROVING SKIN CONDITION USING NONI FRUIT FERMENT | January 2022 | September 2023 | Allow | 20 | 1 | 1 | No | No |
| 17568390 | NUTRITION-BASED METHOD FOR MANAGING ANIMAL BEHAVIOR | January 2022 | January 2024 | Abandon | 25 | 1 | 1 | Yes | No |
| 17560772 | USE OF GINSENG ALCOHOL EXTRACT IN SLEEP-PROMOTING HEALTH CARE PRODUCTS OR FOODS | December 2021 | January 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17557250 | Oral Cannabis Substance and Method of Making Such Substance | December 2021 | January 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17555028 | TONGKAT ALI EXTRACT PRODUCTION PROCESSES AND USES THEREOF | December 2021 | December 2022 | Abandon | 11 | 1 | 0 | No | No |
| 17619617 | METHOD FOR EXTRACTION OF A RAW MATERIAL TO PRODUCE A FORMULATION RICH IN PHYTOCHEMICALS | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17553503 | PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTING, AMELIORATING OR TREATING DIABETES CONTAINING WASP EXTRACT AS ACTIVE INGREDIENT | December 2021 | February 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17545768 | COMPOSITIONS HAVING THE ABILITY TO PROMOTE HEALTHY CHOLESTEROL LEVELS | December 2021 | August 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17457937 | METHOD FOR EXTRACTION OF AN AGENT FROM A PLANT SOURCE | December 2021 | February 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17540766 | INHIBITION OF SARS-CoV-2 VIRUS BY ARUM PALAESTINUM | December 2021 | March 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17540810 | FORMULATIONS INHIBITING SARS-CoV-2 VIRUS | December 2021 | April 2024 | Abandon | 28 | 2 | 1 | No | No |
| 17536979 | COMPOSITIONS AND METHODS FOR INCREASING THE BIOAVAILABILITY OF ONE OR MORE COMPOUNDS | November 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17536877 | COSMETIC COMPOSITION FOR ANTIOXIDANT OR SKIN INFLAMMATION IMPROVEMENT CONTAINING EUPHORBIA SUPINA EXTRACT | November 2021 | January 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17526296 | ANTHOCYANIN POWDER EXTRACT AND PROCESS FOR PRODUCTION | November 2021 | September 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17452029 | HEMP COMPOSITIONS AND METHODS OF MAKING THE SAME | October 2021 | December 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17604841 | PHARMACEUTICAL COMPOSITION COMPRISING MIXTURE EXTRACT OF COPTIS RHIZOME AND SCHIZONEPETA TENUIFOLIA AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE | October 2021 | October 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17467319 | Therapeutic Mixture with Oregano Oil for Herpes Infections | September 2021 | October 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17466139 | USE OF HEMOLYMPH OR HEMOLYMPH COMPONENTS TO REGENERATE, REPAIR AND RESTORE THE SKIN BARRIER | September 2021 | June 2025 | Allow | 45 | 4 | 1 | No | No |
| 17460262 | PHARMACEUTICAL COMPOSITION COMPRISING THE EXTRACT OF CANNABIS SATIVA AS AN EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING OF OBESITY | August 2021 | February 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17407004 | SUPPLEMENT THAT ENHANCES INTRACELLULAR CONCENTRATION OF BIOACTIVE MOLECULES THROUGH INHIBITION OF MULTIDRUG RESISTANT (MDR) EFFLUX PUMPS | August 2021 | June 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17406500 | BUTTER PREPARATION PROCESS | August 2021 | February 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17401594 | METHOD AND APPARATUS FOR PRODUCING CANNABIS SMOKE RESIN | August 2021 | December 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17427380 | METHODS OF TREATING CANCER USING A COMBINATION OF TUMOR MEMBRANE VESICLES AND METFORMIN | July 2021 | October 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17421714 | Anticancer Activity of Buddleja Saligna Compositions | July 2021 | May 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17364996 | PROCESS FOR PRESERVING THE HUSK AND USE OF RAMBUTAN (NEPHELIUM LAPPACEUM) IN FOOD PRODUCTS | July 2021 | September 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17365035 | BITTER GANODERMA LUCIDUM SPORE POWDER AND PREPARATION METHOD THEREOF | July 2021 | August 2023 | Allow | 25 | 1 | 0 | No | No |
| 17362707 | COMPOSITION FOR TREATING VITILIGO | June 2021 | January 2024 | Abandon | 30 | 2 | 0 | Yes | No |
| 17358553 | SYSTEMS AND METHODS FOR PRODUCING A KAVA LIQUID DIETARY SUPPLEMENT | June 2021 | December 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17353956 | PROBIOTIC SKIN FORMULATIONS | June 2021 | May 2024 | Allow | 35 | 4 | 1 | Yes | No |
| 17416881 | BIOLOGICALLY ACTIVE SUBSTANCE, METHOD FOR MANUFACTURING SAME AND USE THEREOF AS AN AGENT FOR PROTECTING A BIOLOGICAL TISSUE | June 2021 | April 2025 | Allow | 45 | 3 | 1 | Yes | No |
| 17352259 | Method of Fermenting Soybeans or other Oil Crops by Edible and Medicinal Fungi | June 2021 | May 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17352278 | COMPOSITIONS OF COFFEE BEAN PRODUCTS, WHOLE HEMP PRODUCTS AND L-THEANINE | June 2021 | June 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17414595 | TWO-DOSAGE-FORM ESSENCE AND PREPARATION METHOD THEREOF | June 2021 | October 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17348011 | SYSTEMS AND METHODS FOR TREATING A DYSBIOSIS USING FECAL-DERIVED BACTERIAL POPULATIONS | June 2021 | June 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17341064 | METHODS FOR FAT REDUCTION OR ELIMINATION OF LIPID DROPLETS | June 2021 | November 2022 | Allow | 18 | 0 | 1 | Yes | No |
| 17339556 | Composition for Sterilization of Tree Cutting Devices and a Method of Use Thereof | June 2021 | April 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17303598 | Herbal Energy Tea | June 2021 | May 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17336745 | THERAPY FOR PROMOTING CELL GROWTH | June 2021 | February 2025 | Abandon | 45 | 4 | 0 | Yes | No |
| 17335875 | CANNABIS PLANT FORMULATIONS AND METHODS OF DELIVERY | June 2021 | April 2024 | Abandon | 35 | 1 | 2 | Yes | No |
| 17293825 | METHODS FOR PREPARING PLATELET RELEASATE | May 2021 | January 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17308459 | SKINCARE COMPOSITIONS CONTAINING CANNABIDIOL | May 2021 | January 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17307814 | BEETROOT-CONTAINING COMPOSITION | May 2021 | January 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17246698 | Systems and Methods for Producing a Kava Liquid Dietary Supplement | May 2021 | November 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17240834 | NUTRIENT COMPOSITION ABLE TO INHIBIT QUORUM SENSING | April 2021 | April 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17301977 | TOPICAL COSMETIC COMPOSITIONS | April 2021 | March 2025 | Abandon | 47 | 5 | 1 | No | No |
| 17224554 | RESPIRATORY TREATMENTS USING SALMONID OIL COMPOSITIONS | April 2021 | March 2024 | Abandon | 35 | 2 | 1 | Yes | No |
| 17221437 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY RESPONSE | April 2021 | May 2023 | Allow | 25 | 2 | 1 | Yes | No |
| 17221411 | COMBINED FUNGAL COMPOSITION FOR MODULATING INFLAMMATORY RESPONSE | April 2021 | May 2023 | Allow | 25 | 3 | 1 | No | No |
| 17217967 | REPELLANT FORMULATION AND METHOD | March 2021 | February 2025 | Allow | 46 | 3 | 1 | Yes | Yes |
| 17214339 | POLYPHENOL BLEND OF CURCUMIN EXTRACT AND POMEGRANATE EXTRACT AND METHODS OF IMPROVING IMMUNE RESPONSE | March 2021 | June 2025 | Allow | 51 | 4 | 1 | Yes | No |
| 17210461 | Pharmaceutical Composition for Promoting Neurogenesis and Method for Promoting Neurogenesis and Inhibiting Senescence of Brain Neurons | March 2021 | April 2025 | Allow | 49 | 6 | 1 | No | No |
| 17194625 | NERVE GROWTH PROMOTER AND METHOD FOR PRODUCING SAME, INTERNAL PREPARATION, MEDIUM ADDITIVE, CELL DILUTION ADDITIVE, MEDIUM, CELL DILUTION, ANTIOXIDANT AND METHOD FOR PRODUCING SAME, EXTERNAL PREPARATION, AND WOUND TREATMENT AGENT AND METHOD FOR PRODUCING SAME | March 2021 | October 2023 | Allow | 31 | 0 | 0 | No | No |
| 17267086 | EXTRACELLULAR VESICLES LOADED WITH AN EXOGENOUS MOLECULE | February 2021 | December 2024 | Abandon | 47 | 2 | 1 | Yes | No |
| 17170735 | COMPOSITION COMPRISING AN ESSENTIAL OIL AND ITS PACKAGING THEREOF | February 2021 | February 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17264497 | COSMETIC OR DERMATOLOGICAL COMPOSITIONS | January 2021 | May 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17157139 | COMPOSITIONS COMPRISING THEANINE, S-ADENOSYLMETHIONINE (SAMe), AND/OR MAGNOLIA AND PHELLODENDRON | January 2021 | February 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17126757 | COMPOSITIONS, METHODS, AND KITS RELATING TO OAK LEAF EXTRACT SUPPRESSION OF CITRUS HUANGLONGBING (HLB) IN CITRUS | December 2020 | April 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17123688 | ENHANCED NON-HORTICULTURE FOOD SUPPLY BIO-SECURITY SYSTEM | December 2020 | May 2024 | Abandon | 41 | 1 | 1 | Yes | No |
| 17121292 | USE OF HEMOLYMPH OR HEMOLYMPH COMPONENTS FOR THE TREATMENT AND PREVENTION OF INFLAMMATION AND DRY SKIN | December 2020 | May 2025 | Allow | 53 | 4 | 1 | Yes | No |
| 15734650 | WORM PRODUCTS AND METHODS OF USE | December 2020 | May 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17059810 | EXTRACT AND DERMATOLOGICAL COMPOSITION COMPRISING SAME, FOR TREATING SENSITIVE SKIN | November 2020 | October 2023 | Allow | 34 | 3 | 1 | Yes | No |
| 17103766 | WATER-SOLUBLE, FULL-SPECTRUM, CANNABIS COMPLEX AND METHOD OF PRODUCTION | November 2020 | May 2024 | Abandon | 41 | 3 | 0 | Yes | No |
| 17053362 | FORMULATIONS COMPRISING NATURAL HYDROSOLS AND USES THEREOF | November 2020 | August 2024 | Abandon | 45 | 3 | 1 | No | No |
| 17053040 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING EXTRACTS OF ANEMONE RADDEANA, LONICERA SPECIES, AND ARALIA ELATA CONTAINING HIGH CONCENTRATION OF ANTITUMOR SAPONINS, AND METHOD FOR PREPARING SAME | November 2020 | December 2023 | Allow | 38 | 3 | 1 | No | No |
| 17052090 | HERBAL MEDICINES FOR TREATING POLYCYSTIC KIDNEY DISEASES | October 2020 | October 2023 | Abandon | 36 | 3 | 1 | Yes | No |
| 17049446 | PREPARATIONS CONTAINING ANTHOCYANINS FOR USE IN THE INFLUENCE OF CARDIOVASCULAR CONDITIONS | October 2020 | May 2025 | Abandon | 55 | 6 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOECKELMAN, JACOB A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BOECKELMAN, JACOB A works in Art Unit 1655 and has examined 230 patent applications in our dataset. With an allowance rate of 34.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner BOECKELMAN, JACOB A's allowance rate of 34.8% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BOECKELMAN, JACOB A receive 1.95 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BOECKELMAN, JACOB A is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +53.2% benefit to allowance rate for applications examined by BOECKELMAN, JACOB A. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.0% of applications are subsequently allowed. This success rate is in the 21% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.3% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 95.2% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.